Financials

v3.22.1
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 8,138 $ 6,037
Restricted cash 211 295
Receivables 218 112
Inventory 293 293
Prepaid expenses and other current assets 749 480
Discontinued operations - current assets 24 12
Total current assets 9,633 7,229
Property and equipment, net 368 420
Other assets 48 48
Operating lease right-of-use asset 269 297
Total assets 10,318 7,994
Current liabilities:    
Accounts payable 468 795
Accrued clinical trials expenses 39 9
Other accrued liabilities 320 314
Operating lease liability, current 114 112
Deferred grant revenue 211 295
Discontinued operations - current liabilities 1,126 1,144
Total current liabilities 2,278 2,669
Operating lease liability, non-current 158 187
Total liabilities 2,436 2,856
Stockholders' equity:    
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized, 12,039,421 and 9,914,158 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively. 12 10
Additional paid-in capital 386,465 381,183
Accumulated deficit (378,595) (376,055)
Total stockholders' equity 7,882 5,138
Total liabilities and stockholders' equity $ 10,318 $ 7,994

Source

v3.22.1
CONDENSED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenues:    
Total revenues $ 192 $ 682
Operating expenses:    
Cost of goods sold 0 110
Research and development 1,409 1,877
General and administrative 1,322 1,327
Total operating expenses 2,731 3,314
Loss from operations (2,539) (2,632)
Other expense:    
Interest expense, net 0 (1)
Other expense, net (1) (8)
Other expense, net (1) (9)
Net loss $ (2,540) $ (2,641)
Basic net loss per common share $ (0.24) $ (0.28)
Diluted net loss per common share $ (0.24) $ (0.28)
Weighted average shares used in computing basic net loss per common share 10,729 9,289
Weighted average shares used in computing diluted net loss per common share 10,729 9,289
License revenue    
Revenues:    
Total revenues $ 3 $ 2
Product revenue    
Revenues:    
Total revenues 0 111
Grant revenue    
Revenues:    
Total revenues $ 189 $ 569

Source

v3.22.1
CONDENSED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net loss $ (2,540) $ (2,641)
Adjustments to reconcile loss to net cash used in operating activities:    
Depreciation and amortization 52 55
Non-cash interest expense 0 1
Stock-based milestone payment 50 0
Stock-based compensation 253 248
Other 1 (5)
Changes in operating assets and liabilities:    
Receivables (106) 487
Inventory 0 110
Prepaid expenses and other assets (281) (241)
Accounts payable (350) (482)
Deferred grant revenue (84) 0
Other accrued liabilities 41 (157)
Net cash used in operating activities (2,964) (2,625)
Cash flows from financing activities:    
Net proceeds from equity offering 4,980 8,841
Net proceeds from the exercises of common stock warrants 1 0
Net cash provided by financing activities 4,981 8,841
Net increase in cash, cash equivalents and restricted cash 2,017 6,216
Cash, cash equivalents and restricted cash at beginning of period 6,332 5,413
Cash, cash equivalents and restricted cash at end of period $ 8,349 $ 11,629

Source